Flyte Aviation, Inc. (VTAK) Form 8-K — Nov 16, 2026
Flyte Aviation reported record Q3 2026 revenue of $1.838 million, up 145% sequentially, with flight hours up 129% and more than 99% of flights fulfilled on its own fleet. Aviation is now the sole continuing operation following the classification of the legacy MedTech segment as discontinued operations. The company reported a net loss of $15.1 million, including a $13.3 million non-cash impairment on MedTech assets held for sale, with a $1.9 million loss from continuing operations and just $2.4 million in cash remaining at quarter end. On November 1, Flyte signed a non-binding LOI to sell Catheter Precision's VIVO and LockeT assets by year-end 2026.
Key figures
- Revenue
- 1838000
- Cash Position
- 2400000
- Medtech revenue
- 280000
- Impairment charge
- 13300000
- Jets coming online q4
- 3
- Medtech revenue yoy growth pct
- 24
- Time flown per leg avg minutes
- 52
- Loss from continuing operations
- 1900000
- Flight hours sequential growth pct
- 129
- Medtech revenue sequential growth pct
- 4
- Aviation revenue sequential growth pct
- 145
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.